ArticleCancer discovery2022
Repurposing Vandetanib plus Everolimus for the Treatment of
Open access · hybridAbstract readCase Reports
In one paragraph
Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Harnessing artificial intelligence for pediatric health: Current trends and future opportunities.iScience · 2026Review
- From Molecular Alterations to the Targeted Therapy: Treatment of Thalamic Glioma in Pediatric Patients.International journal of molecular sciences · 2026Review
- Integrative machine learning-guidedRSC advances · 2025Article
- Decoding Gene Expression Changes in Cerebral Tumors: Before and After Radiotherapy.Medicinal research reviews · 2025Review
- The transcription factor LHX2 mediates and enhances oncogenic BMP signaling in medulloblastoma.Cell death and differentiation · 2025Article
- Computational drug repurposing: approaches, evaluation of in silico resources and case studies.Nature reviews. Drug discovery · 2025Review
- Establishment of xenografts and methods to evaluate tumor burden for the three most frequent subclasses of pediatric-type diffuse high grade gliomas.Journal of neuro-oncology · 2025Article
- Advances in the Repurposing and Blood-Brain Barrier Penetrance of Drugs in Pediatric Brain Tumors.Cancers · 2025Review
- Inhibitory effect of luteolin on the metabolism of vandetanibFrontiers in pharmacology · 2025Article
- Article
- Radiotherapy plus temozolomide with or without anlotinib in H3K27M-mutant diffuse midline glioma: A retrospective cohort study.CNS neuroscience & therapeutics · 2024Article
- Preliminary Evidence of the Use of Generative AI in Health Care Clinical Services: Systematic Narrative Review.JMIR medical informatics · 2024Review
- PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo.Scientific reports · 2024Article
- Everolimus in pituitary tumor: a review of preclinical and clinical evidence.Frontiers in endocrinology · 2024Review
- Advances in Treatment of Diffuse Midline Gliomas.Current neurology and neuroscience reports · 2023Review
- Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters.Nature reviews. Cancer · 2023Review
- Epidemiology, Diagnostic Strategies, and Therapeutic Advances in Diffuse Midline Glioma.Journal of clinical medicine · 2023Review
- A novel CDK4/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma.Journal of neuro-oncology · 2023Article
- Towards Standardisation of a Diffuse Midline Glioma Patient-Derived Xenograft Mouse Model Based on Suspension Matrices for Preclinical Research.Biomedicines · 2023Article
- Multimodal MRI radiomic models to predict genomic mutations in diffuse intrinsic pontine glioma with missing imaging modalities.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 10 institutions in 6 countries.
Diana M CarvalhoDivision of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.
Peter J RichardsonBenevolentAI, London, United Kingdom.ORCID 0000-0001-7813-041X
Nagore OlacireguiLaboratory of Molecular Oncology, Hospital Sant Joan de Déu, Barcelona, Spain.
Reda StankunaiteMolecular Diagnostics, Royal Marsden Hospital NHS Trust, Sutton, United Kingdom.ORCID 0000-0003-3977-7020
Cinzia LavarinoLaboratory of Molecular Oncology, Hospital Sant Joan de Déu, Barcelona, Spain.ORCID 0000-0002-9630-3676
Valeria MolinariDivision of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.
Elizabeth A CorleyChildren & Young People's Unit, Royal Marsden Hospital NHS Trust, Sutton, United Kingdom.ORCID 0000-0002-8660-9938
Daniel P SmithBenevolentAI, London, United Kingdom.
Ruth RuddleDivision of Cancer Therapeutics, Institute of Cancer Research, London, United Kingdom.ORCID 0000-0003-0025-8872
Adam DonovanDivision of Cancer Therapeutics, Institute of Cancer Research, London, United Kingdom.
Akos PalDivision of Cancer Therapeutics, Institute of Cancer Research, London, United Kingdom.
Florence I RaynaudDivision of Cancer Therapeutics, Institute of Cancer Research, London, United Kingdom.
Sara TemelsoDivision of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.ORCID 0000-0001-6017-8503
Alan MackayDivision of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.
John P OveringtonMedicines Discovery Catapult, Alderley Edge, United Kingdom.ORCID 0000-0002-5859-1064
Anne PhelanBenevolentAI, London, United Kingdom.
David SheppardBenevolentAI, London, United Kingdom.
Andrew MackinnonChildren & Young People's Unit, Royal Marsden Hospital NHS Trust, Sutton, United Kingdom.
Bassel ZebianDepartment of Neurosurgery, Kings College Hospital NHS Trust, London, United Kingdom.
Safa Al-SarrajDepartment of Clinical Neuropathology, Kings College Hospital NHS Trust, London, United Kingdom.
Ashirwad MerveInstitute of Neurology, University College London Hospitals, London, United Kingdom.ORCID 0000-0001-9715-1849
Jeremy PryceSouth West London Pathology, St George's Hospital NHS Trust, London, United Kingdom.
Jacques GrillDepartment of Pediatric and Adolescent Oncology and INSERM Unit U891, Team "Genomics and Oncogenesis of Pediatric Brain Tumors," Gustave Roussy and University Paris-Saclay, Villejuif, France.ORCID 0000-0003-4773-3001
Michael HubankMolecular Diagnostics, Royal Marsden Hospital NHS Trust, Sutton, United Kingdom.ORCID 0000-0002-2901-0742
Ofelia CruzPaediatric Oncology, Neuro-Oncology Unit, Hospital Sant Joan de Déu, Barcelona, Spain.ORCID 0000-0001-7102-3283
Andres Morales La MadridPaediatric Oncology, Neuro-Oncology Unit, Hospital Sant Joan de Déu, Barcelona, Spain.
Sabine MuellerUniversity Children's Hospital, Zurich, Switzerland.
Angel M CarcabosoLaboratory of Molecular Oncology, Hospital Sant Joan de Déu, Barcelona, Spain.ORCID 0000-0002-8485-426X
Fernando CarcellerChildren & Young People's Unit, Royal Marsden Hospital NHS Trust, Sutton, United Kingdom. chris.jones@icr.ac.uk fernando.carceller@icr.ac.uk.ORCID 0000-0003-3094-3758
Chris JonesDivision of Molecular Pathology, Institute of Cancer Research, London, United Kingdom. chris.jones@icr.ac.uk fernando.carceller@icr.ac.uk.
Institute of Cancer Research · GBHospital Sant Joan de Déu Barcelona · ESRoyal Marsden NHS Foundation Trust · GBRailway Repair and Engineering Works (Slovakia) · SKKing's College - North Carolina · USInserm · FRMedicines Discovery Catapult · GBSouth West London and St George's Mental Health NHS Trust · GBUniversity College Hospital · GBUniversity of California, San Francisco · US
Funding
Cancer Research UK 13982Cancer Research UK 22897Cancer Research UK 23536Cancer Research UK A23536Medical Research Council G0902001
Abstract
Somatic mutations in
Indexed as
Activin Receptors, Type IAnimalsAntineoplastic Combined Chemotherapy ProtocolsBrain Stem NeoplasmsChildChild, PreschoolDrug RepositioningEverolimusFemaleGliomaHumansMaleMiceMice, SCIDPiperidinesQuinazolinesActivin Receptors, Type IACVR1 protein, humanEverolimusPiperidinesQuinazolinesvandetanib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.